CIC
REGN icon

Cornercap Investment Counsel’s Regeneron Pharmaceuticals REGN Stock Holding History

Cornercap Investment Counsel’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,441
Closed -$1.01M – 655
2022
Q1 		$1.01M Buy
+1,441
New +$912K 0.11% 315
2019
Q1 		– Sell
-7,574
Closed -$2.83M – 444
2018
Q4 		$2.83M Buy
+7,574
New +$2.77M 0.44% 79

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Cornercap Investment Counsel's REGN Position: Q2 2022 in Review

Cornercap Investment Counsel sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 1,441 shares — an estimated $1.01M sold.

Cornercap Investment Counsel first reported a position in REGN in Q4 2018 and held it in 2 quarters. The position peaked at $2.83M in Q4 2018. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

  • Cornercap Investment Counsel reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Cornercap Investment Counsel sold 1,441 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $1.01M.
  • Cornercap Investment Counsel first reported a position in Regeneron Pharmaceuticals in Q4 2018 and held it in 2 quarters.
  • Cornercap Investment Counsel's Regeneron Pharmaceuticals position peaked at $2.83M in Q4 2018.
  • 1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Cornercap Investment Counsel's 13F filing for Q2 2022, filed 15 Aug 2022.